FDA Grants Approval for Torsemide ANDA217239 by Micro Labs
The FDA has granted approval for the ANDA217239 application for Torsemide submitted by Micro Labs.
Published: July 12, 2026
Updated: July 12, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Diuretic
Company: Micro Labs
Asset: Torsemide
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Micro Labs
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Micro Labs' generic Torsemide represents a significant shift in the competitive landscape of the diuretic market. Pharma companies must evaluate how this new entry will affect their market share and pricing strategies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies of Micro Labs for Torsemide.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.